NDA 200655 · Feinstein
Fluorodopa F18
Fluorodopa F-18 · Intravenous
NovelLast checked: Nov 19, 2026Latest source record: Dec 11, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 10, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
5 Phase 3, 10 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 15, 2021.
Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. Fluorodopa F 18 Injection is a radioactive diagnostic agent indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- FLUORODOPA F18 · FLUORODOPA F-18 1-40mCi/ML · SOLUTION, INTRAVENOUS · Prescription
- FLUORODOPA F18 · FLUORODOPA F-18 1-40mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluorodopa F-18" as an intervention, any sponsor and status, largest first.
- Diagnosis of PheochromocytomaRecruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004847 · 3,000 participants (planned) · Start Mar 22, 2000 · Primary completion Nov 30, 2048
Drug: ([18F]-DOPA); ([18F]-6F-DA) · For: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Sites: Bethesda, Maryland
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001277 · 1,553 participants · Start Dec 15, 1993 · Primary completion Mar 11, 2020
Drug: 68Ga-Dotatate; 18F-DOPA · For: Hyperparathyroidism; Hypercalcemia; Parathyroid Neoplasm and 2 more
Sites: Bethesda, Maryland
- 18F-DOPA II - PET Imaging OptimizationPivotal-lookingRecruiting
University of AlbertaAcademic, hospital or other
NCT04706910 · 800 participants (planned) · Start Jan 20, 2021 · Primary completion Dec 2027
Drug: 18F-DOPA; Furosemide Injection · For: Congenital Hyperinsulinism; Neuroblastoma; Parkinson Disease and 3 more
Sites: Edmonton, Canada
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyPivotal-lookingCompleted
University of AlbertaAcademic, hospital or other
NCT03042416 · 400 participants · Start Jun 29, 2017 · Primary completion Mar 5, 2021
Drug: 18F-DOPA · For: Congenital Hyperinsulinism; Neuroblastoma; Neuroendocrine Tumors and 2 more
Sites: Edmonton, Canada
- Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT07935889 · 292 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2035
Drug: Fluorodopa F 18; Temozolomide · For: Glioblastoma, IDH-Wildtype
Sites: Scottsdale, Arizona; Jacksonville, Florida; Albert Lea, Minnesota · 8 sites in all
Cook Children's Health Care SystemAcademic, hospital or other
NCT02021604 · 250 participants (planned) · Start Oct 9, 2013 · Primary completion Jan 2028
Drug: Fluorodopa F 18 · For: Congenital Hyperinsulinism; Insulinoma
Sites: Fort Worth, Texas
- Ultralow Dose PET Imaging of 18F-FDOPAEnrolling by invitation
Akiva MintzAcademic, hospital or other
NCT07542158 · 200 participants (planned) · Start May 12, 2025 · Primary completion Jun 30, 2030
Drug: 18F-FDOPA · For: Heathy Volunteer; Parkinsonian Syndromes; Neuroendocrine (NE) Tumors and 1 more
Sites: Englewood, New Jersey
- Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's DiseasePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00220272 · 183 participants · Start Jan 2004 · Primary completion Mar 2007
Drug: SR57667B · For: Parkinson Disease
Sites: Laval, Canada; Helsinki, Finland; Paris, France · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
Rinne JO, Portin R, Ruottinen H, et al. · Arch Neurol 2000 · Clinical Trial, Controlled Clinical Trial
Sponsor: Feinstein
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.